The complementary policy of Chinese and Western medicine was promoted, and 6 pharmaceutical stocks rose by more than 1%

[pharmaceutical network industry trends] affected by the promotion of complementary policies between Chinese and Western medicine, pharmaceutical stocks are generally better A few days ago, according to incomplete statistics, the pharmaceutical companies with a rise of more than 1% in pharmaceutical stocks were: Stone pharmaceutical now rose by 3.15%; Sinopharm also rose by 1.73%; Chinese traditional medicine rose by 2.51%; pioneer pharmaceutical rose by 1.61%; Fosun Pharmaceutical rose by 2.27%; Sansheng pharmaceutical rose by 1.85% Sinopharm group, which is known as the "leading pharmaceutical company in Hong Kong stock market", now its subsidiary Sinopharm xinnuowei has issued the semi annual performance forecast for 2019 In the first half of the year, the net profit attributable to the parent company was about 123.4 million yuan to 143 million yuan, an increase of 12% to 30% in advance During the reporting period, the company carried out all work in an orderly manner, and its production and operation continued to develop steadily; relying on a good market customer base, the company's business scale continued to expand, its sales revenue grew steadily, and its expected performance rose year on year Sinopharm has become one of the three leading pharmaceutical enterprises in China, which is transforming from "Imitation Based" to "combination of creation and imitation" In 2018, revenue reached 20.889 billion yuan, a year-on-year increase of 41%; net profit reached 9.046 billion yuan, a year-on-year increase of 316.7% The significant increase in performance is mainly due to the impact of consolidated statement after the acquisition of 24% equity of Beijing Taide Chinese traditional medicine Chinese traditional medicine is a sale of Chinese patent medicine, Chinese herbal medicine, Chinese herbal pieces and other enterprises According to the announcement of Chinese traditional medicine, in 2018, the turnover was 11.259 billion yuan, an increase of 35.0% year on year; the gross profit was 6.194 billion yuan, an increase of 33.1% year on year According to the announcement, the turnover increased by 35.0%, mainly due to the sustained and rapid development of the traditional Chinese medicine formula granules business and the rapid expansion of the decoction pieces business The gross profit margin is 55.0%, which is mainly due to the increase in the proportion of Herbal Pieces business, while its gross profit margin is lower than other businesses According to the public information of pioneer medicine, pioneer medicine and its subsidiaries have achieved product coverage in the treatment fields of Ophthalmology, digestive department, cardiovascular department, respiratory department, dental department, wound care, anesthesia department, etc In 2018, avant-garde medicine achieved revenue of 1.624 billion yuan, a year-on-year decrease of 24.6% According to the announcement, the decrease in the company's revenue is mainly due to the decrease in sales of the products of primo due to the impact of some self media questioning events In addition, during the reporting period, according to the relevant arrangements of the transition agreement between the group and elkang and Beijing Novartis, the group and Beijing Novartis have gradually transferred the market of elkang ophthalmic drugs Fosun Pharma's business covers the whole industry chain of pharmaceutical health, including pharmaceutical manufacturing and R & D, medical services, medical devices and medical diagnosis, pharmaceutical distribution and retail Among them, drug manufacturing and research and development are the core, and medical services are the development focus On March 26th, Fosun Pharmaceutical disclosed its annual report In 2018, the company realized revenue of 24 billion 918 million yuan, an increase of 34.45% year-on-year, net profit attributable to shareholders of the listed company of 2 billion 708 million yuan, and net profit attributable to shareholders of the listed company deducting non recurring profit and loss of 2 billion 90 million yuan, a decrease of 13.33% and 10.92% respectively compared with the same period last year The company said that the increase in operating revenue was mainly due to the increase in revenue of core products, the contribution of new M & A enterprises and the expansion of medical service business during the reporting period The decrease of net profit is mainly due to the decrease of asset disposal income, the increase of investment in innovative research and development and business layout during the reporting period Sansheng pharmaceutical is a high-tech enterprise integrating research and development, production and sales of biological drugs, which has a leading position in China's biopharmaceutical industry According to the announcement, in 2018, Sansheng pharmaceutical achieved a total operating revenue of about 4.584 billion yuan, an increase of 22.7% over the same period last year; gross profit of about 3.707 billion yuan, an increase of 21.2% over the same period last year; net profit of about 1.166 billion yuan, an increase of 29.0% over the same period last year; R & D investment of about 360 million yuan, an increase of 40.9% over the same period last year